Terminated PHASE2 INTERVENTIONAL 7-arm NCT00543959

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

An Efficacy and Tolerability Study of MK0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Sponsor: Merck Sharp & Dohme LLC

Conditions Diabetes Mellitus Type 2

Interventions Comparator: Placebo (unspecified) Comparator: pioglitazone MK0533

Updated 11 times since 2017 Last updated: Jun 22, 2015 Started: Jun 30, 2006 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study is being discontinued based on data suggesting that none of the doses tested demonstrated both glycemic \& body fluid benefits vs. the comparitor

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Diabetes Mellitus Type 2 trials with similar outcome

Browse all Diabetes Mellitus Type 2 trials

Listed as NCT00543959, this PHASE2 trial focuses on Diabetes Mellitus Type 2 and remains terminated or withdrawn. Sponsored by Merck Sharp & Dohme LLC, it has been updated 11 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jun 2022 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jun 2022 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 6 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.